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V/n assessed the influence of CKD on 6 leeding in 200
patients with ADS via retrospective chart analysis.
Using K/DOOl guideiines to stratify patients based
on GFR, no differences in documented bieeding or
antithrombotic utilization were observed among the
groups. Due to increased mortality risk of patients
with CKD from cardiovascuiar disease, assessing
bonefihtorisk ratios of various medical interventions
is cruciaL
Introduction
Chronic kidney disease (CKD) is increasing in prevw
lence in the US among the adult population. Cardim
ascular disease including acute coronary syndromes
ACS accounts for nearly half of all deaths among
CR1) palientrU Reasons for this increased risk of
eardios acular death and morbidity include a higher
prevalence of cardiac risk factors in patient’ us oh
renal dysi unction ineludinso smoking. sin slipidemia.
hypertension, and l’pcrh lu’vs tinemiaa Addi
tO maNy, it has been shown that medical treatment of
.\CS using5iandard medications such as beta—block—
erci aspirin. thromholvties. as well a utilization of
cl’euiu’ous revauenlarizaton techniques arc lesc
commonly implemented in patients with CKD
compared to those with normal renal lunetion.
Reported expianatioiw fur this d iserepanea include
concerns about bleedinc eomnhieation as yell as
the limited available data e”nn’iu the treatment
and uteunes of patients, with CKI). The landniark
neat trial pud tile USC of medical trcatmuiit
aiD rueedures after nlvoeardlal ufaretlon hanetr P1-
cal l\ e\eluded pat tents with CR1) or eild-StOCC renal
disease ESRD. Further. theten no data esarnninc
tile effect renal sir sturetlon nason tIlt risk of’hieedute
in patients beine treated for ACS.
The ,\atiunal Kidney FAundation NKI 1. in an et -
to improve the quality and outcomes of treatment
iOn patients with ki.dnev disease, launched. the Kidney
Disease Outcomes Quali.tv Initiative (KIDOQI’). H
This initiative which stratitie.s patients based on their
vlorneru.lar fil.trati•.on rate (GFR), provides c.ri..teria for
en aluating and classifyingkidney disease, an approach
to risk stratification, and evidence-based practice
guidelines fur continuous care and therapy of CKI).
Current work is aimed at formulating practice guide
lines for the management of cardiovascular disease,
especially ACS in CKD patients.
This study sought to defIne bleeding risks in CKI)
patients medically treated forACS. U. sing. the K!DOQI
CKD guidelines to stratify patients based on their
degree of kidney disease, we examined the impact
of renal dysfunction on documented bleeding events
and use of antithromhotic therapy.
Methods
our study was approved b appropriate institutional
ren ens hoards. Our collective was identified by a
computerized search of discharge diagnoses for ACS
and CR1) at two matorhospitals in Honolulu. HI, tronl
ianuarx gq 1 to June 01)03. \‘ledical records of these
rots mere aeees’ed. and 901) patients with CR1) us crc
rardomir selected trom tho’w adillitted tor ACS.
All patients fulfilled American College of Card ioi
og\ American Heart.-\ssueiation (ACC’AHA)erileria
t’or un ‘table ingi nao.r acute itluocardi ci mtarction
i. All patients were also required to fulfill criteria
icr CKD. deli ned or screenoic purposes as havltlO a
eruui creatinine concentration of >1.5 mwdl. Crc
atnne clearance snas. then calculated for all itieni
accot’dine to the ockerult-Gault formula: CrCl
I—Ni
—agei. ‘ sserht (k’i . seinnl ertatinine (mmdii
I. 1 5 . Snhsequentlc. patients \vCi’t orouped- Into
nile ot tnnr elases ua’ed on \KF’ K.’DOQI e.iideline’
kP (dRill ‘w (fR
S nice -1 (‘il R I 5’i . or Stave’ 5 GFR <15.
Excluded tuna tO s tudr were psitt’tts who underwent
(.‘.-\I3Oorrc cci\ ed thu nlbol t:c therapy during their
i’iospi ta Ii zat ion. aswe ii as. those presenting with as’ site
renal iaiure.
Bi’rc flute haracteristic s and. c.i.inicuul data were
extracted from, all charti.: meetlng tile above criteri.a.
UP no “ElM I criteria, they were• evaluated ‘.fo.r hi.eed
ing conipl’ications, both major and minor events:’ (‘‘16).
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Table 1 .— Baseline Characteristics of Chronic Kidney Disease Patients with Acute Coronary Syndrome. Based on
K/DOQI Stage
Charactehstic Stage 2 iGFR 60-89i Stage 3 (GFR 30-59) Stage 4 (GFR 1 5-29 Stage 5 (GFR <15
Patients, n 11 38 59 92
Male (%.( 6 i55( 32(84) 32(4) 42 (46(
Hemog)conrlgdh 13.8—’) ‘2.6*24 ii’.i:
P:atee:s.’03ui 2915W 154 226.3-776 249.8—)03 232Z7771.9
Hypertension 70) 1 i.iOO) 3079) 55 (93) 77 (8$i
IDDM 1%) 2 i18) 10 (261 21 (36) 29 (32)
NIDDM (%( 2(15) 8 (21) 14(241 14 (151
Prior History of Ml t% 2 15) 11 79) 32 :541 38(41
Continuous data a oresented as mean SD.
At p-values were non-sgnificant. except for number of females p=C,003) and base:ine nemogiobin p70.001
None of tne patients in ths conort bad any accumented h:storv: of b)eeoing disorders.
0DM = lnsu’n-dependent Diabetes Me::tus, NIDDM = Noninsuin-dependent D:aberes Melitus. Ml = Myocardial lntarct:on.
Figure 1.— Frequency of Documented Bleeding
Finally, the in-hospital utilization ofASA.elopidogrel.
GPllbHla-inhibitors, enoxaparin, and IV—heparin was
recorded.
Differences between K1DOQI groups were ana
lszed usiiiANOVAorchi—square test. as appropriate.
Statistical analysis was performed hr using the SPSS
statistical package. ersion 100 (SPSS Institute.
Inc., Chicago. EL). Continuous data are expressed as
mean ± SI) and categorical data as frequencies and
percentages.
Results
We revies’ ed 200 patients ‘s ith CXI) admitted
(or ACS. No increased hicedine tendencies, such
as known bleeding diatheses. a family history of
bleeding disorders, or chronic outpatient Coumadin
use, were identified in this cohort. Baseline charac—
ten-ties between each K;DOQI group ss crc similar
Fable It, except fir the Stage 3 group has ing fewer
women compared to the S;tage 5 group I (70 s. 54’
p=O,003. Differences in baseline hemoglobin from
Stage 2 to Stage 5 (13.8 mg/dl ± 1.9 vs. 11.2 mg/dl
± 1.8; p<0.O0 I) were also noted. Finally, there was
an increasing trend in the number of patients per
K/DOQI group. from Stage 2 to Stage 5.
The oeral1 bleeding rate was 277 for the cohort.
There s’ere no significant differences among the
groups in lrequencv or documented bleeding Stage 2,
3, 4, 5: 15%, 2802, 27%, 29% respectively; p=0.872
(NS)) or in mean numberof PRBCstransfused(Stage
2, 3, 4. 5: 0.5. 1.0. 1.0, 1.5 respectisely; p=0.5249
(NS( (Figure I
No significant differences were ohsered in the
utilization 01 aspirin. clopidogrel. (3PIIbIIIa—inhibi—
tors. enoxaparin. or IV—heparin among the K DOQI
groups (Table 2). Finally, regression analysis did not
identify K/DOQI Stage as an indicator for increased
bleeding.
Discussion
Despite the event rate being higher than historic
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Table 2.— Utilization of Antithrombotic Therapy. Based on K!DOQI Stage
Treatment Stage 2 (GER 60-89) Stage 3 GFR 30-59) Stage 4 (GFR 15-29: Stage 5 (GFR <15)
Aspr:n 6 55: 28 74i 41 (69: 62 :67:
C(op;dogwl 6 :55 9 24( 19 32: 19 21
GP1IbHIa lnh.b.tor 4 36 4 1 8 14 4 .4
E9cxaawn 4 36 ‘3 34: 2 35: 2426:
Hepart 4:36. 4:11; 1.3;22: 1820;









Stage 2 (GFR 60-89) Stage 3 (GFR 30-59) Stage 4 (GFR 15-29) Stage 5 (GFR <15)
-- !1gp’ N ‘b; gf aR2O Ln :s Itanst.sed.
K DOQJ Stage of CK[) had any influence on bleed-
na rt--k- among thosc receivng medtcal tre:llment
fr \C.S . \Vhilc not statisticall\ signitleant. the
bleeding rate ot patIent’S in Stace 2 was lower than
in other stages. Possible explanations include the
ba number of patients a ithin this croup. or perhaps
tIns might represent a threshold of renal dysfunction.
where a transition trom Stage 2 to Stae 3 ma he
associated with increased bleeding risk. We will need
lnraer sample 5i7,e to better evaluate the relationship.
While we did observe an increasing trend in the t(Gal
number of PRBCs transfused as the degree of kidney
diseisc worsened, this tuna represent the cliahtl\ lo er
baseline hemoglobin 1ev cI found in thos.e subjects in
Stage 4 and 5 being transfused to a similar goal. ar
perhaps this i an earl\ sign of increased bleeding
aniorig those vs ith more advanced kidney disgase,
Perhaps stronger conclusions could be drawn if spe
citic indications far blood transfusions were known.
Finally, no signiflcant differences in the utilization
of ant ithromhotic therapy were bserved between
K DOQ[ groupvT tic is in conlrnst to previous studies
that Ii ave rcpt rted decreased ue l’ antithrombot i c
rherap syith increasing renal d slunction, This
study demonstrated [hnt similar medical therapy
among pattents with dccltning renal ‘unction did not
result in an increased bleeding rate. The major impli
cation otthic linding is in the treatment of patients in
4 and Stage 5. With an over—representation 01
cardios ascular disease occurring antong those a ith
CKD, more work is needed to improve outcomes in
this population, Because our study is retrospective
in design. we can make no cone lusions: however it
may add to the limited data that the degree of renal
failure univ not he a limiting factor when determin
tIe appropriate medical treatment of EKE) patients
with .-\CS.
The overall bleedina rate uf this cohort vs as 27,
higher than reported bleeding rates amin non—
renal disease patients vs ith ,-\(.S. Patietits with
renal d\ slunction demonstrate an increased risk
of bleeding, due to defacts in platelet function and
metabolism, defects in vascular endothelial/smooth
muscle cell metabolism, and the influence of anemia
on hemostais,ar There is also data suggesting that
CKD patients have an increased tendeuu toa ards
occult gastro-intestinal bleeding while undernoing
dialysis treatment. Hoa ever, since our report is
33S
retrospective in design. directcausesof bleedmg could
not be determined, although it is likely that multiple
metabolic or pathologic influences affect bleeding in
this collective. The principal observation from this
report is that while there appears to he an increased
overall bleeding event rate in those ss ith CKD. there
does not appear to any difference as the degree of
kidney disease worsens.
While there “crc no statistically significant differ
ences in the rise of sarious medical therapies between
K DOQI groups, the os eral I titil/ation of antithrom—
bone therap ss as much lower than reported in patients
with ACS and normal renal fLinction. While this
study did not address mortalit raters of the cohort.
other studies has e found a consistent and large mor—
talitv benefit with increased use of antithromhotics,
regardless of the ses erity of renal dvsfunction.’
Several considerations should he made when in
terpreting this study. This cohort ssas derived from a
retrospect is e chart analy sis and is prone to limitations
inherent to such studies. This includes the possihilit
of unmeasured factors inhitiencing the data and the in
ability to generate cause and effect conclusions. While
all bleeding events ssere documented, many records
failed to document the location of the bleed. Thus.
conclusions regarding the possible contraindications
of patients not receiving antithromhotic therap can
not be made. Additionally, potential participant bias
may ecist. due to large number ot Stage 4 and Stage
5 patients treated at surveyed hospitals.
In conclusion, this study found that the severity
of renal dysfunction did not influence bleeding risk
among patients medically treated for ACS. Currently,
all trials regarding treatment and outcomes after ACS
have excluded patients with renal insufficiency. Large
prospective clinical trials that include patients with
CKD are needed to properly assess actual bleeding
risks and recommend appropriate interventions in this
high-risk population. Presumably, with the develop
ment of more aggressive treatment strategies both in
the acute setting and in primary prevention, improve
ments in the quality olcare (Yf patients with CKD may
he realized.
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